These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 31368669

  • 1. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA, Mauermann ML, Grogan M, Coelho T.
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [Abstract] [Full Text] [Related]

  • 2. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I.
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [Abstract] [Full Text] [Related]

  • 3. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H.
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [Abstract] [Full Text] [Related]

  • 4. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M, Norman K, Sanchorawala V, Siddiqi OK, Hughes D.
    J Cardiovasc Pharmacol; 2021 May 01; 77(5):544-548. PubMed ID: 33657048
    [Abstract] [Full Text] [Related]

  • 5. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
    Zibert A, Hüsing-Kabar A, Schmidt H.
    Dtsch Med Wochenschr; 2019 Oct 01; 144(20):1438-1443. PubMed ID: 31594020
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA, Salvo EM, Tran D, Amass L, Stewart M, Cameron C.
    Curr Med Res Opin; 2020 May 01; 36(5):799-808. PubMed ID: 32011182
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
    J Clin Pharmacol; 2020 Jan 01; 60(1):37-49. PubMed ID: 31322739
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M.
    Expert Opin Pharmacother; 2019 Mar 01; 20(4):473-481. PubMed ID: 30489166
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
    Dyck PJB, Coelho T, Waddington Cruz M, Brannagan TH, Khella S, Karam C, Berk JL, Polydefkis MJ, Kincaid JC, Wiesman JF, Litchy WJ, Mauermann ML, Ackermann EJ, Baker BF, Jung SW, Guthrie S, Pollock M, Dyck PJ.
    Muscle Nerve; 2020 Oct 01; 62(4):509-515. PubMed ID: 32654156
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD, Dasgupta NR, Monia BP.
    Neurodegener Dis Manag; 2019 Feb 01; 9(1):25-30. PubMed ID: 30561247
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.
    JAMA Cardiol; 2019 May 01; 4(5):466-472. PubMed ID: 30878017
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM, Zhang K, Lenihan DJ, Witteles R.
    Am J Med; 2022 Apr 01; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.